The coronavirus pandemic has turned life upside down around the world, with many workers losing their jobs, economies plummeting and parents worried about reopening schools.
Of all the coronavirus’s qualities, perhaps the most surprising has been that seemingly healthy people can spread it to others. This trait has made the virus difficult to contain, and continues to challenge efforts to identify and isolate infected people.
NEW BRUNSWICK, New Jersey, Aug. 5, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen's SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the United States following approval or Emergency Use Authorization by the U.S. Food and Drug Administration (FDA).
:strip_exif(true):strip_icc(true):no_upscale(true):quality(65)/cloudfront-us-east-1.images.arcpublishing.com/gmg/FHF6MCXQDNB7ZHEJ6ODVWLVWE4.jpg)
